Plain-English translation of NCT07160946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large study following 6,000 people with hepatitis B who have signs of liver disease. Researchers want to see if using an artificial intelligence system alongside regular blood tests and imaging scans can help catch liver cancer earlier than standard monitoring alone. The goal is to improve outcomes for people at high risk.
Liver cancer related to hepatitis B is a major health problem worldwide, especially in China. By catching cancer earlier, doctors can treat it when it's most treatable. This study tests whether adding AI technology to routine care can spot warning signs faster and save more lives.
You likely qualify if…
You likely don't qualify if…
You will be assigned to either routine monitoring or routine monitoring plus AI support. Either way, you'll visit the clinic every 24 weeks (or every 8-12 weeks if you're at very high risk) for blood tests, imaging scans of your liver, and liver function checks. The AI group will have their results analyzed by a computer system to help catch early warning signs. The study will track you over time to see which approach catches liver cancer earlier.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Sponsor
Sun Yat-sen University
Enrollment target
~6,000 participants
Started
May 2025
Primary completion
December 2032
Age range
30 Years – 75 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bingliang Prof. Lin
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.